12/13/2021 11:28:40 AM
Kazia Therapeutics Appoints Karen Krumeich As CFO
11/15/2021 11:05:13 AM
Kazia Therapeutics Appoints John Friend As Chief Medical Officer
6/30/2021 10:02:24 AM
Kazia Updates On Paxalisib And EVT801 Clinical Programs
6/15/2021 10:04:09 AM
Kazia Collaborates With Cornell University For Phase II Study Using Paxalisib-Ketogenic Diet For Glioblastoma
6/7/2021 8:29:01 AM
Kazia Therapeutics Enrols First Patient In Phase II Study Of Paxalisib In Primary CNS Lymphoma
4/19/2021 5:39:51 AM
Evotec Grants Kazia Worldwide License To Develop, Manufacture, And Commercialise EVT801
3/29/2021 5:21:08 AM
Kazia Therapeutics Enters Licensing Agreement With Simcere Pharmaceutical To Develop Paxalisib